Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Qureshi
Abrar A
AA
Fischer
Michael A
MA
D000279:Administration, Cutaneous; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014481:United States
D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus